Improving the immunogenicity of E. coli FimH via multivalent display on I53-50 nanoparticles

This study demonstrates that displaying the *E. coli* FimH antigen on I53-50 nanoparticles significantly enhances its immunogenicity, eliciting robust receptor-blocking antibodies in mice and non-human primates comparable to high-dose monomeric formulations, thereby validating a promising nanoparticle-based vaccine strategy for preventing urinary tract infections.

The Gist

The Big Problem: The "Uninvited Guest"

Imagine your bladder is a high-security building. Every year, about 150 million people get kicked out of their homes by a very persistent intruder: a bacteria called E. coli. This bacteria causes Urinary Tract Infections (UTIs).

The bacteria has a special tool to break in: a tiny, sticky grappling hook on its surface called FimH. This hook grabs onto the "doormats" (sugar molecules) on your bladder walls, anchoring the bacteria so it can't be washed away by your urine. Once it's stuck, it causes infection.

The Old Strategy: A Weak Shield

Scientists have tried to make a vaccine to stop this. The idea was to show your immune system a picture of the "grappling hook" (FimH) so it can build antibodies (security guards) to block it.

However, there was a problem. When scientists made a simple, single copy of this hook and injected it, the body's security system barely noticed. It was like trying to get a guard dog's attention by whispering a single word. The dog (your immune system) needed a loud, repetitive shout to wake up. To get a reaction, doctors had to give patients huge doses of the vaccine mixed with very strong, complex chemicals (adjuvants) to scream "Look at this!"

The New Solution: The "Bouncy Castle" Strategy

The researchers in this paper came up with a clever new idea. Instead of showing the immune system one lonely grappling hook, they built a bouncy castle (a protein nanoparticle called I53-50) and stuck 60 grappling hooks all over its surface.

Think of it this way:

• The Old Way: Holding up one single key to a security guard. The guard is confused.
• The New Way: Putting 60 keys on a giant, spinning, colorful Ferris wheel and rolling it right up to the guard. The guard can't ignore it!

This "Ferris wheel" is the I53-50 nanoparticle. It's a tiny, self-assembling ball made of proteins. The researchers attached the FimH hooks to this ball, creating a "multivalent" display.

The Experiment: Testing the Ferris Wheel

The team tested two versions of this vaccine on mice and monkeys:

1. Version A: The Ferris wheel with the basic grappling hook (FimH-Lectin Domain).
2. Version B: The Ferris wheel with a "super-stabilized" grappling hook (FimH-DSG). This version is like a hook that has been reinforced with steel so it doesn't bend or break, making it easier to manufacture.

They compared these "Ferris wheels" against the old "single key" method.

The Results: A Resounding Success

The results were amazing:

• The "Ferris Wheel" won easily: Just one or two shots of the nanoparticle vaccine created a massive army of antibodies.
• Less is more: The nanoparticle vaccine worked just as well as the old method, even though they used 10 times less of the actual antigen (the hook).
• Simpler ingredients: The nanoparticle vaccine worked so well that it didn't need the super-strong, complex chemical screamers (adjuvants). It only needed a standard, safe booster (aluminum hydroxide), which is used in many common vaccines like the tetanus shot.
• Blocking the door: The antibodies created by this vaccine were excellent at physically blocking the bacteria's grappling hook, preventing the bacteria from sticking to the bladder.

Why This Matters

This study is a big deal for three reasons:

1. It works for bacteria: Most nanoparticle vaccines have been used for viruses (like SARS-CoV-2). This proves the "Ferris wheel" strategy works great for bacteria too.
2. It's cheaper and easier: Because the "super-stabilized" hook (FimH-DSG) is easier to make in a factory, and because the vaccine doesn't need expensive, complex adjuvants, this could lead to a cheaper, more accessible vaccine for UTIs.
3. It's a blueprint: This gives scientists a new playbook. If they find other bacteria that are hard to fight with current vaccines, they can try sticking those bacteria's "hooks" onto these I53-50 Ferris wheels to make them more effective.

The Bottom Line

The researchers figured out how to turn a weak, whispering vaccine into a loud, attention-grabbing one by organizing the ingredients into a neat, repetitive package. This could lead to a future where UTIs are prevented by a simple, effective shot, saving millions of people from pain and recurring infections.

Technical Summary

1. Problem Statement

Urinary tract infections (UTIs), primarily caused by uropathogenic E. coli (UPEC), represent a significant public health burden, affecting approximately 50% of women globally. Recurrent UTIs are common, and antibiotic resistance is a growing concern.

• The Target: The FimH adhesin, located at the tip of Type 1 pili, is a promising vaccine candidate because it mediates bacterial attachment to the urinary tract epithelium via binding to mannosylated uroplakins.
• The Challenge: Previous studies demonstrated that recombinant monomeric FimH is poorly immunogenic. To elicit receptor-blocking antibodies, soluble FimH requires multiple doses and potent, complex adjuvants (e.g., QS-21/MPLA). Furthermore, FimH exists in dynamic "open" (low-affinity) and "closed" (high-affinity) conformations. The "open" conformation is a better vaccine target for blocking receptor binding, but stabilizing this state in full-length constructs has been difficult.

2. Methodology

The study utilized a two-component protein nanoparticle platform, I53-50, to display FimH antigens multivalently.

• Antigen Design:
  • FimHLD: The lectin domain only.
  • FimH-DSG: A recently developed, conformationally stabilized full-length FimH variant (lectin + pilin domains) locked in the "open" conformation.
  • Both antigens were genetically fused to the N-terminus of the I53-50A trimeric subunit via a flexible linker.
• Nanoparticle Assembly:
  • The antigen-bearing trimers (I53-50A-FimH) were mixed with the I53-50B pentameric subunit (or a non-assembling control, 2obx-wt) in a 1.1:1 molar ratio.
  • This self-assembled into 60-mer nanoparticles displaying 60 copies of the antigen.
• Characterization:
  • In Vitro: Size exclusion chromatography (SEC), SDS-PAGE, negative stain electron microscopy (nsEM), dynamic light scattering (DLS), and biolayer interferometry (BLI) were used to confirm monodispersity, correct assembly, and conformational integrity.
  • In Vivo Models:
    • Mice (CD-1): Immunized with nanoparticle immunogens (1 µg antigen/dose) vs. soluble monomers (10 µg prime/1–5 µg boost) vs. non-assembling controls. Adjuvants included Aluminum Hydroxide (Alhydrogel) for nanoparticles and QS-21/MPLA for potent monomer controls.
    • Non-Human Primates (NHPs): Cynomolgus macaques were immunized with nanoparticle immunogens (50 µg lectin domain equivalent) vs. soluble FimH-DSG (QS-21/MPLA) vs. placebo.
• Assays:
  • Binding: Luminex assays for anti-FimH IgG titers and ELISA for anti-scaffold (I53-50) antibodies.
  • Function: Yeast mannan binding inhibition assays to measure the ability of serum antibodies to block FimH-receptor interaction (ID50).

3. Key Contributions

• Platform Extension: Successfully extended the I53-50 nanoparticle platform, previously validated for viral and protozoan antigens, to bacterial antigens (FimH).
• Conformational Stabilization: Demonstrated that the stabilized FimH-DSG antigen can be successfully displayed on nanoparticles while maintaining its "open" conformation, which is critical for inducing blocking antibodies.
• Adjuvant Reduction: Showed that nanoparticle display can obviate the need for complex, potent adjuvants. Nanoparticle formulations using simple Aluminum Hydroxide outperformed or matched soluble antigens formulated with potent liposomal QS-21/MPLA.
• Dose Sparing: Achieved equivalent or superior immune responses with a 10-fold lower antigen dose compared to soluble monomeric controls.

4. Key Results

• Nanoparticle Assembly: Both FimHLD-I53-50 and FimH-DSG-I53-50 assembled into monodisperse particles (~34–38 nm) with high purity and conformational integrity, confirmed by binding to the conformation-specific mAb 926.
• Mouse Immunogenicity:
  • Antibody Titers: Both nanoparticle immunogens elicited robust anti-FimH IgG responses (GMTs $10^3$–$10^4$ µg/mL) after two doses.
  • Comparison: Nanoparticles formulated with Alhydrogel induced antibody levels comparable to soluble FimH-DSG formulated with QS-21/MPLA, despite using a 10-fold lower antigen dose.
  • Functional Activity: Nanoparticles elicited strong receptor-blocking activity (ID50 up to $10^4$) after two doses. In contrast, soluble monomers (even with potent adjuvants) showed negligible blocking activity after two doses, requiring a third dose to reach similar levels.
• NHP Immunogenicity:
  • Response Magnitude: All three groups (FimHLD-NP, FimH-DSG-NP, and soluble FimH-DSG) elicited high serum IgG titers ($\sim 10^5$ U/mL) after the third dose.
  • Functional Activity: Receptor-blocking titers increased significantly after the third dose for all groups, with no significant difference between the nanoparticle and soluble antigen groups.
  • Scaffold Response: Nanoparticle immunogens induced robust anti-I53-50 scaffold antibodies, whereas soluble monomers did not.
  • Mucosal Response: Urine samples showed increased antigen-specific IgG post-vaccination, though titers were lower than serum levels.

5. Significance

• Vaccine Development: This study provides critical preclinical data supporting the development of a FimH-based vaccine for UTIs. It demonstrates that multivalent display on I53-50 can overcome the inherent poor immunogenicity of bacterial subunit antigens.
• Manufacturing and Formulation: The use of the stabilized FimH-DSG antigen combined with a simple aluminum adjuvant offers a more manufacturable and potentially safer formulation compared to complex adjuvanted soluble proteins.
• Broad Applicability: The results suggest that the I53-50 platform is a versatile tool for designing antibacterial vaccines, particularly for small, monomeric antigens that fail to elicit protective immunity in their soluble form. This approach could be applied to other bacterial targets where receptor-blocking antibodies are the desired mechanism of action.
• Clinical Translation: Given that I53-50-based vaccines (e.g., for SARS-CoV-2) have already entered clinical trials and received licensure, the rapid translation of this FimH platform to human trials is feasible.